Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMBRELLA phase 1/2 trial of isatuximab-based combinations in relapsed or refractory multiple myeloma
2024-514988-25-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 10
01
Overview
Phase 2 trial of isatuximab, pomalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Primary endpoints: Recommended dose determination, VGPR rate or better and 1 more. Planned start Mar 2021; status: authorised.
02
Drugs
isatuximabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-514988-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514988-25-00.